Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07716020

XPAD European Feasibility Study

A prospective, single arm, non-randomized European feasibility study to evaluate the safety and performance of the XPAD conduit in patients with peripheral arterial occlusive disease (PAOD), scheduled to undergo elective lower-limb, above or below the knee, bypass surgery.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants with peripheral artery occlusion who require elective lower-limb bypass surgery
  • Participant has Rutherford grade 3 or 4 occlusive vascular disease and TASC C or D lesions.
  • At least 18 years of age at screening
  • Suitable anatomy while avoiding joints (assessed by a pre-procedural contrasted CT scan or previous angiogram assessed up to 90 days prior to baseline)
  • Participant has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent
  • Participant has been informed and agrees to pre- and post-procedure follow-up, including follow-up angiography
  • Life expectancy of at least 24 months

Exclusion criteria

  • Participant requires, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure.
  • Stroke or myocardial infarction event within 6 weeks of the procedure or evidence of prior massive stroke (Modified Rankin Scale 3 or above)
  • History of acute arterial occlusion requiring an emergent intervention within the last 12 months
  • Severe chronic renal insufficiency (serum creatinine >2.5 mg/dL) or undergoing hemodialysis
  • Previous renal transplant
  • Uncontrolled arterial hypertension (BP >200 mmHg) at 2 successive readings
  • Uncontrolled or poorly controlled diabetes
  • Abnormal blood values that could influence participant recovery and or/ graft hemostasis
  • Reduced liver function, defined as: >2x the upper limit of normal for serum bilirubin, International Normalized Ratio (INR) >1.5 or prothrombin time (PT) >18 seconds
  • Any active local or systemic infection
  • Known heparin- induced thrombocytopenia, active bleeding disorder and/or any coagulopathy or thromboembolic disease
  • Allergies to study device (nitinol) or agents/medication, such as contrast agents, aspirin or NOACs, that can't be controlled medically
  • Previous enrolment in this study
  • Participant is participating in another study
  • Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives
  • Any other condition which, in the judgement of the investigator would preclude adequate evaluation for the safety and performance of the study conduit

Intra-operative exclusion criteria:

  • Unsuitable anatomy to implant the XPAD conduit (e.g. target vessel diameter smaller than anticipated; severe calcification)

Treatment and study plan

XPAD conduit

Device

The XPAD bypass conduit is a sterile, restorative biodegradable polymer-based vascular conduit, consisting of a tubular structure with a 33cm length and 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The XPAD conduit is in a straight configuration and may be implanted in the lower limb for elective bypass surgery.

Primary outcomes

  1. Primary patency rate

    Time frame: 12 months post-implant

    Primary patency defined as the interval between conduit implantation and the first intervention to maintain or restore patency

  2. Freedom from device-related SAE

    Time frame: Day 1, 30 days, 6 months, and 12 months post-implant

Secondary outcomes

  1. Implantation success rate

    Time frame: Day 1

    Implantation success defined as a technically successful XPAD conduit implantation in the planned configuration, free from kinking and tension in the anastomoses, and a patent XPAD conduit at the moment of discharge.

  2. Freedom from Major Bleeding events

    Time frame: Day 1, 30 days and 6 months post-implant

    Major Bleeding defined as type 3, 4 or 5 bleeding according to the Bleeding Academic Research Consortium (BARC) classifications

  3. Patency (primary, primary assisted, and secondary) rates

    Time frame: 6, 12, 24, 36, 48 and 60 months post-implant

    Primary patency defined as the interval between conduit implantation and the first intervention to maintain or restore patency.

    Assisted primary patency defined as the interval between conduit implantation and the first occlusion (thrombosis), including interventions (operative or endovascular) aimed to maintain the functionality the conduit.

    Secondary patency defined as the interval between conduit implantation and abandonment with or without interventions (operative or endovascular) aimed to maintain the functionality the conduit, including occurrence of a censored event (death, change of modality, loss of follow-up).

  4. Freedom from device-related SAE

    Time frame: 24, 36, 48 and 60 months post-implant

  5. Rate of wound/conduit infections

    Time frame: 30 days, 6, 12, 24, 36, 48 and 60 months post-implant

  6. Freedom from Major Amputations

    Time frame: 30 days, 6, 12, 24, 36, 48, and 60 months post-implant

    Major Amputation defined as any amputation that results in limb shortening

  7. Freedom from all-cause mortality

    Time frame: 30 days, 6, 12, 24, 36, 48, and 60 months post-implant

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Xeltis

Industry

Registry information

Official study title

Prospective, Non-randomized, European Feasibility Clinical Study to Assess the Safety and Performance of the Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit.

Important dates

Study start
2026
Primary completion
2028
Study completion
2032
First posted
Jul 21, 2026
Registry last updated
Jul 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.